MGC026, which is a TOP1i-based ADC, is undergoing a phase 1 dose-escalation study in patients with advanced solid tumors. The ...

Second is MGC028, a Topo 1 inhibitor-based ADC that ... Stephen. This afternoon MacroGenics reported financial results for the year ended December 31, 2024, which highlight our financial position.

MGC026 and MGC028,” said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. “Finally, we have determined that the results of the TAMARACK Phase 2 study of vobra duo in mCRPC do not ...

The company has a promising ADC portfolio, with MGC026 and MGC028 in clinical development, and MGC030 in preclinical studies. Macrogenics Inc (NASDAQ:MGNX) successfully completed the sale of ...

We look forward to building upon this momentum in 2025 as we work to advance our novel pipeline of clinical product candidates, including lorigerlimab, MGC026 and MGC028,” said Scott Koenig, M.D., ...

On MGC028, are you able to comment on how far ... everyone for joining us on this call and for continued interest in MacroGenics. A special thanking to our employees for their continued commitment ...

Second is MGC028, a TOP1i inhibitor-based ADC that ... Thank you, Stephen. This afternoon, MacroGenics reported financial results for the year ended December 31, 2024, which highlight our ...